CDSCO Regulatory Update
India’s pharmaceutical regulatory landscape continues to evolve, with recent CDSCO notifications introducing new controls on prescription medicines and specific drug combinations. Two important developments issued in August 2026 are particularly relevant for pharmaceutical manufacturers, marketers, importers and distributors.
1. Proposed Addition of Four Drugs to Schedule H1
Through Draft Notification G.S.R. 745(E), dated 19 August 2026, the Ministry of Health & Family Welfare has proposed adding four additional drugs to Schedule H1 of the Drugs Rules, 1945:
- Flupentixol
- Zopiclone
- Gabapentin
- Carisoprodol
The proposal would bring these medicines under the additional prescription-control requirements applicable to Schedule H1 drugs. The notification is currently a draft, with stakeholders invited to submit objections and suggestions before finalization.
2. Restriction on Chlorpheniramine + Phenylephrine FDCs
On 18 August 2026, CDSCO issued S.O. 4595(E) concerning fixed-dose combinations containing Chlorpheniramine Maleate + Phenylephrine Hydrochloride.
The notification extends the restriction to all FDC formulations containing these two ingredients, with a mandatory warning that the formulation shall not be used in children below four years of age. The warning is required on the label, package insert and promotional literature. The notification took effect upon publication.
What Pharmaceutical Manufacturers Should Review
These developments highlight the importance of maintaining up-to-date regulatory controls across:
- Product formulation & composition
- Labelling and package inserts
- Prescription classification
- Regulatory documentation
- Quality control & analytical testing
- Promotional materials
- Product registration and compliance records
Manufacturers should particularly review products containing the affected substances and assess whether their labels, technical documents and internal compliance procedures require updating.
Analytical Testing & Quality Compliance
Regulatory compliance goes beyond formulation and documentation. Pharmaceutical products should be supported by reliable analytical data covering applicable quality attributes, including:
- Assay & Related Substances
- Identification
- Dissolution
- Content Uniformity
- Impurities & Degradation Products
- Residual Solvents
- Elemental Impurities
- Microbiological Quality
- Stability Testing
Advanced analytical platforms such as HPLC, GC-MS/MS, LC-MS/MS, ICP-MS and UV-Visible spectroscopy can support comprehensive pharmaceutical quality evaluation.
Why These Updates Matter
The latest CDSCO actions demonstrate continued regulatory focus on prescription control, patient safety and responsible medicine use. For pharmaceutical companies, proactive regulatory monitoring is essential to identify affected products and implement required changes before they become a compliance issue.
Stay Updated. Test Precisely. Remain Compliant.
Eureka supports pharmaceutical manufacturers with comprehensive analytical testing and quality evaluation to help meet evolving Indian and international regulatory requirements.
Important: G.S.R. 745(E) is currently a draft proposal, not a final Schedule H1 amendment. The final notification should be monitored before treating the proposed additions as legally effective.